| Literature DB >> 25983991 |
Yvo W J Sijpkens1, Noeleen C Berkhout-Byrne1, Ton J Rabelink1.
Abstract
Management of severe chronic kidney disease (CKD) involves dealing with medical, nursing and psychosocial problems and therefore warrants support from a multidisciplinary team. In the Kidney Disease Outcomes Quality Initiative (KDOQI) classification system of CKD, preparation for renal replacement therapy has been recommended in CKD stage 4, characterized by a reduction in the estimated glomerular filtration rate (GFR) of <30 ml/min. In this article we share our approach to perfecting predialysis care. Tools are given to make an estimation of the progression of kidney disease. Also the prevention and treatment of metabolic complications and cardiovascular risk management are summarized. Finally, the possibilities for dialysis but even more important, aiming for pre-emptive transplantation, are being discussed. Using a multidisciplinary integrated care approach predialysis care has come of age.Entities:
Keywords: chronic kidney disease; pre-emptive transplantation; predialysis
Year: 2008 PMID: 25983991 PMCID: PMC4421146 DOI: 10.1093/ndtplus/sfn117
Source DB: PubMed Journal: NDT Plus ISSN: 1753-0784
Progression factors: treatment and targets
| Factor | Target | Treatment |
|---|---|---|
| Hypertension | Systolic blood pressure <130 mmHg | Salt restriction, exercise, RAAS-blockade, diuretics, calcium entry blocker |
| Proteinuria | 24 h protein <1 g/day | Salt and protein restriction, RAAS-blockade, diuretics |
| Hyperlipidaemia | LDL-cholesterol <2.5 mmol/l | Saturated and trans-fat restriction, statine, ezetrol |
| Obesity | Waist circumference <94 cm (♂), <80 cm (♀) | Calory and mono-disaccharide restriction, increased physical activity, increasing muscle mass |
| Smoking | 0 cigarettes | Ask, advise, assess, assist, arrange |
| Hyperglycaemia | HbA1c <7% | Weight reduction, pioglitazon, insulin |
| Hyperphospataemia | Phosphate <1.2 mmol/l | Phosphate restriction, phosphate binders |
| Hyperuricaemia | Uric acid <0.35 mmol/l | Purine and fructose restriction, allopurinol |
Metabolic complications: treatment and targets
| Complication | Target | Treatment |
|---|---|---|
| Anaemia | Haemoglobin 6.8–7.5 mmol/l, ferritin 100–500 μg/l, transferring saturation (20–50%) | Darbepoëtine/epoëtine β, ferrofumarate/sulfate, vitamin C |
| Hypovitaminosis D | 25(OH)D >75 nmol/l | Cholecalciferol |
| Hypocalcaemia | Calcium 2.1–2.4 mmol/l | Calcium carbonate/acetate, alfacalcidol, phosphate reduction |
| Hyperphosphataemia | Phosphate <1.2 mmol/l | Phosphate restriction, phosphate binders |
| Hyperparathyreoidism | PTH 7–12 pmol/l | Phosphate reduction, cholecalciferol, alfacalcidol, paricalcitol |
| Metabolic acidosis | Bicarbonate >22 mmol/l | Protein restriction, sodium bicarbonate |
| Hyperkalaemia | Potassium 3.5–5.5 mmol/l | Potassium restriction, diuretics, resonium |
| Hyperuricaemia, gout | Uric acid <0.35 mmol/l | Fructose and purine restriction, allopurinol |
| Cardiovascular disease | LDL-cholesterol <2.5 mmol/l | Statin, aspirin |
Fig. 1Sharp increase in the probability of achieving pre-emptive transplantation at the Leiden University Medical Center (fam: living related transplantation; LURD: living unrelated renal donation).
Fig. 2Early preparation for dialysis. AVF: arteriovenous fistula.
Fig. 3Integrated predialysis care concept: administration of care that promotes self-management. By utilization of the intrinsic strengths of each individual, patients are empowered to face the challenges of their illness.
Fig. 5KDOQI targets a: haemoglobin: >6.8 mmol/l; ferritin: 100– 500 μg/l; transferring saturation: >20%; b: calcium: <2.4 mmol/l; phosphate: <1.5 mmol/l; PTH: 7–12 pmol/l.
Fig. 4Multidisciplinary approach. Our patient is central to all our actions. Psychological, social and spiritual guidance goes hand in hand with medical care. The multidisciplinary team supports the patient on his road to acceptance and at all times endeavours to promote self-management.